License ProMab’s CAR Technology

With the ability to support discovery and development activities—including GMP manufacturing and clinical trial facilities—ProMab can support a range of licensing and partnering models that span discovery, preclinical development, and clinical development. 

Our cell therapy platform includes:

• The ability to generate both mouse and fully human single-chain variable fragment (scFv) for CAR constructs

• 3,000+ hybridoma cell lines

• 10^11 human phage display Fabs

• 5,000+ mouse monoclonal antibodies

• 30+ types of CAR-T and CAR-NK cells targeting different tumor cells and cell lines expressing tumor-specific antigens—covered by 13 patents

• The ability to use immunological modulators, tumor microenviroment (TME) invaders, and checkpoint inhibitors

• Our sensitive real-time cytotoxicity assays (RTCA) for CAR-T cell validation in vitro and ex vivo

• Our in vivo NSG/ NOG xenograft models that can be used to validate the efficacy of CAR-T and CAR-NK cells against solid and hematological cancers

Figure 1. ProMab’s CAR cell engineering platform spans the entire CAR cell process.

Learn more about our CAR-T Cell Development Services

Figure 2. Our patented CAR innovations are designed to improve safety and efficacy while simplifying development.

Our CAR cell therapy platform includes a number of advances in CAR design covered by 20+ patents, and can be implemented in a range of immune cells including T cells and NK cells (Figure 2).

The advantages include:

• Bispecific scFv’s to enable complex antigen recognition. 

ProMab scientists have developed a number of different bi-specific CAR-T cells, including CD19-CD22, to more specifically target tumor antigens and compensate for the loss of a single tumor antigen.

• scFv-enzyme complexes to modulate the TME.

Learn more about this work which is being conducted with Helix Biopharma.

• Novel or mutant co-stimulatory domain to modulate CAR cell activity.

ProMab scientists developed a mutant CD28 domain that decreased cytokine secretion. Additional novel domains, such as GITR, can be used for CAR-T development with the following domains available for research use: EGFR-CAR-T, Mesothelin-CART and Cd19-CAR-T with GITR domain (Learn more in the paper: GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer, Frontiers in Bioscience, June 1, 2018; PMID: 29772559)

• CAR construct in combination with additional genetic material to block checkpoint inhibitors.

CAR-T with knock-down cytokines (IL-6) or check-point inhibitors such as PD-1 are available for development. In addition, combination with self-delivered (SD) RNA (RXi company) can be used with CAR-T cells.

• Inducible caspase-9 as a suicide switch for enhanced safety.

We can use different safety switches to regulate CAR-T cells including truncated EGFR, RQR8 with CD34, Rituximab epitopes, and inducible caspase-9.

• Extracellular Beam™ tag to simplify purification and enable in vivo monitoring.

CAR-tags such as CD19-Beams 1 can be used to image CAR-T cells in vivo (learn more in the paper: FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. Frontiers in Bioscience, 2017; PMID: 28410137)